Physician profile
Roozbeh Sharif
NPI 1396037008
$22,813.01
in general payments reported to CMS, 2019-2025
31 companies · $9,202 in 2025
The $9,202 reported for 2025 was more than what 92% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,040 · 2022: $3,080 · 2023: $6,570 · 2024: $2,920 · 2025: $9,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,900 · Food and Beverage: $6,566 · Travel and Lodging: $2,193 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,900.00 |
| Food and Beverage | $6,565.74 |
| Travel and Lodging | $2,193.20 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $12,282.35 | 2022-2025 | Tyvaso, Tyvaso, Orenitram |
| Genzyme Corporation | $3,295.59 | 2021-2025 | |
| Verona Pharma, INC. | $1,123.43 | 2025 | Ohtuvayre |
| Hill-Rom Company, INC | $875.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $829.46 | 2022-2025 | Fasenra, Airsupra, Breztri |
| Inspire Medical Systems, INC. | $825.21 | 2022-2025 | Inspire |
| Glaxosmithkline, LLC. | $639.36 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $599.05 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Philips North America LLC | $395.82 | 2023-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Electromed, INC. | $367.97 | 2024-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.55 | 2023-2025 | Jascayd, Ofev |
| Baxter Healthcare | $243.91 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Insmed, INC. | $185.33 | 2023-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $167.94 | 2024-2025 | Winrevair |
| Globus Medical, INC. | $164.21 | 2024 | Excelsius3d Imaging System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $145.92 | 2021-2025 | Dupixent |
| Inogen, INC. | $88.06 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Abbvie INC. | $56.10 | 2021 | |
| Zoll Respicardia, INC. | $47.89 | 2024 | Remede System |
| Tactile Systems Technology INC | $36.28 | 2022 | |
| Amgen INC. | $34.00 | 2025 | |
| Vapotherm INC | $27.48 | 2022 | |
| Advanced Respiratory, INC | $24.45 | 2021 | |
| Genentech USA, INC. | $20.43 | 2022 | |
| Itamar Medical INC | $20.18 | 2023 | Watchpatone |
| Optinose US, INC. | $19.02 | 2024 | |
| Mylan Specialty L.P. | $18.02 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roozbeh Sharif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.